The agreement covers the use of SiPore across consumer oral health formulations and establishes a framework for joint research and clinical evaluation, with the objective of enabling future commercialization following clinical validation.

The collaboration marks an important milestone in the continued development of SiPore as a platform technology with multiple application areas, pursued in parallel with Sigrid’s ongoing commercialization within metabolic health, the company states.

Under the terms of the agreement, Sigrid will receive an upfront payment, development and clinical milestones, additional sales-based milestone payments, and ongoing, long-term royalties on net sales.

The agreement is structured as a multi-year, royalty-bearing partnership, with Sigrid’s participation aligned to the long-term commercial success of SiPore-based products in global oral health markets. The structure reflects a shared ambition to build durable value through scientific validation and global scale.

“Oral health is a demanding category where safety, efficacy, and daily usability are critical,” says Damir Konakovic, Head of Oral Health at Sigrid. “This collaboration enables rigorous scientific validation of SiPore in oral health, while leveraging a partner with the capabilities to translate that science into products that can reach consumers globally and at scale.”